The prevalence of Helicobacter pylori infection in Egyptian patients with metabolic associated fatty liver disease | ||||
| Egyptian Journal of Medical Research | ||||
| Volume 6, Issue 1, January 2025, Page 242-255 PDF (614.45 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejmr.2024.268832.1552 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Mohamed Gamal Mohamed ; Abdulrahman Gharib Ewies  ; Mohamed Abdelfattah Elfeki
| ||||
| Internal Medicine Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt. | ||||
| Abstract | ||||
| Background : Helicobacter pylori is a common bacteria that is present in about half of all population. H pylori infection causes atrophic and even metaplastic changes in the stomach; this infection is also linked to peptic ulcer disease and systemic inflammation that alters metabolism. Objective: To investigate the prevelance of H- pylori infection among Egyptian adults its association with Metabolic dysfunction associated fatty liver disease (MAFLD) Methods: The study will involve 200 patients 100 cases and 100 control . Height and weight were measured and calculation of BMI (BMI = kg/m2), waist & hip circumference were measured, Blood pressure was assessed by mechanical monitor (systolic& diastolic). Degree of fibrosis (FIB4, APRI) was measured . H pylori antigen in stool was done. Ultrasonography & Fibroscan of the liver was performed .Results: Our results showed there is a significant difference between both groups (P-value 0.001) regarding the following: The H. pylori were positive in 79% of the case group, while only 33% of the control group were positive. The bright Hepatomegaly was positive in 93% of the case group, and the whole control group was negative (normal). The Fibroscan, the control group had F0 (45%) and F1 (55%) while the distribution among the case group was significantly different F0 (2%), F1 (44%), F2 (38%) and F3 (16%). Conclusion: H.pylori infection is a risk factor for developing MAFLD in Egyptian patients. | ||||
| Keywords | ||||
| H.pylori infection; Liver cirrhosis; MAFLD; fibroscan | ||||
| References | ||||
|
1-Alavinejad, P., Hajiani, E., Parsi, A. et al. Effect of Helicobacter pylori eradication on metabolic profile: an international, multicenter, case-control study. BMC Gastroenterol 22, 507 (2022). https://doi.org/10.1186/s12876-022-02604-3
2- Aumpan, N., Mahachai, V. and Vilaichone, R.-k. Management of Helicobacter pylori infection. JGH Open, 7: 3-15 (2023),. https://doi.org/10.1002/jgh3.12843.
3- Franceschi F, Annalisa T, Teresa DR, Giovanna D, Ianiro G, Franco S, Viviana G, Valentina T, Riccardo LL, Antonio G. Role of Helicobacter pylori infection on nutrition and metabolism. World J Gastroenterol. 2014 Sep 28;20(36):12809-17. doi: 10.3748/wjg.v20.i36.12809.
5- Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al.,. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020 Jul;73(1):202-209. doi: 10.1016/j.jhep.2020.03.039.
6- Xu G, Ma S, Dong L, Mendez-Sanchez N, Li H, Qi X. Relationship of Helicobacter pylori Infection with Nonalcoholic Fatty Liver Disease: A Meta-Analysis. Can J Gastroenterol Hepatol. 2023 Jan 25;2023:5521239. doi: 10.1155/2023/5521239.
7- Wang W., Fan M., Gong R., et al. Helicobacter pylori infection is not an independent risk factor of non-alcoholic fatty liver disease in China. BMC Gastroenterology . 2022;22(1):p. 81. doi: 10.1186/s12876-022-02148-6.
8- Stefan N, Häring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019 Apr;7(4):313-324. doi: 10.1016/S2213-8587(18)30154-2.
9- Li W, Zhang J, Ma J, Li Z, Zhang L, Zhang Y et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial BMJ 2019; 366 :l5016 doi:10.1136/bmj.l5016.
10- Rakha, M., Saleh, O., Abdelgawad, M.S. et al. Helicobacter pylori infection in patients with metabolic syndrome, with or without nonalcoholic fatty liver disease. Egypt Liver Journal 11, 7 (2021). https://doi.org/10.1186/s43066-020-00071-7.
11- Abo-Amer YE, Sabal A, Ahmed R, Hasan NFE, Refaie R, Mostafa SM, Mohamed AA, Khalil M, Elagawy W, Abd-Elsalam S. Relationship Between Helicobacter pylori Infection and Nonalcoholic Fatty Liver Disease (NAFLD) in a Developing Country: A Cross-Sectional Study. Diabetes Metab Syndr Obes. 2020 Mar 2;13:619-625. doi: 10.2147/DMSO.S237866.
12- Wang W, Fan M, Gong R, Zhang Y, Zeng J, Xu S, Lin R. Helicobacter pylori infection is not an independent risk factor of non-alcoholic fatty liver disease in China. BMC Gastroenterol. 2022 Feb 24;22(1):81. doi: 10.1186/s12876-022-02148-6.
13- Chen J, Xing Y, Zhao L, Ma H. The Association between Helicobacter pylori Infection and Glycated Hemoglobin A in Diabetes: A Meta-Analysis. J Diabetes Res. 2019 Sep 9;2019:3705264. doi: 10.1155/2019/3705264. PMID: 31583248; PMCID: PMC6754895.
14- Mohammadifard M, Saremi Z, Rastgoo M, Akbari E. Relevance between Helicobacter pylori Infection and Non-Alcoholic Fatty Liver Disease in Birjand, Iran. J Med Life. 2019 Apr-Jun;12(2):168-172. doi: 10.25122/jml-2019-0012.
15- Fan N, Peng L, Xia Z, Zhang L, Wang Y, Peng Y. Helicobacter pylori Infection Is Not Associated with Non-alcoholic Fatty Liver Disease: A Cross-Sectional Study in China. Front Microbiol. 2018 Jan 31;9:73. doi: 10.3389/fmicb.2018.00073.
16- Ning L, Liu R, Lou X, Du H, Chen W, Zhang F, Li S, Chen X, Xu G. Association between Helicobacter pylori infection and nonalcoholic fatty liver disease: a systemic review and meta-analysis. Eur J Gastroenterol Hepatol. 2019 Jul;31(7):735-742. doi: 10.1097/MEG.0000000000001398.
| ||||
|
Statistics Article View: 193 PDF Download: 99 |
||||
